Adaptive Biotechnologies Corporation ADPT
$ 4.45
0.57%
Quarterly report 2024-Q3
added 11-07-2024
Adaptive Biotechnologies Corporation Balance Sheet 2011-2024 | ADPT
Annual Balance Sheet Adaptive Biotechnologies Corporation
2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Debt |
75 M | 44.6 M | -27.3 M | - | -60 M | -55 M | -85.3 M | - | - | - | - | - | - |
Long Term Debt |
131 M | 125 M | 107 M | - | - | - | - | - | - | - | - | - | - |
Long Term Debt Current |
9.38 M | 9.23 M | 5.06 M | 3.53 M | - | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | - | - | - | 263 M | 568 M | 566 M | - | - | - | - | - | - |
Total Current Liabilities |
88 M | 110 M | 114 M | 105 M | 78.3 M | - | - | - | - | - | - | - | - |
Total Liabilities |
353 M | 393 M | 319 M | 373 M | 341 M | 591 M | 587 M | - | - | - | - | - | - |
Deferred Revenue |
48.6 M | 64.1 M | 80.5 M | 73.3 M | 61 M | 12.7 M | 14 M | - | - | - | - | - | - |
Retained Earnings |
-1.14 B | -919 M | -719 M | -512 M | -365 M | -296 M | -249 M | - | - | - | - | - | - |
Total Assets |
661 M | 857 M | 923 M | 1.12 B | 912 M | 333 M | 362 M | - | - | - | - | - | - |
Cash and Cash Equivalents |
65.1 M | 90 M | 139 M | 123 M | 96.6 M | - | - | - | - | - | - | - | - |
Book Value |
308 M | 464 M | 604 M | 743 M | 571 M | -258 M | -225 M | - | - | - | - | - | - |
Total Shareholders Equity |
308 M | 464 M | 604 M | 743 M | 571 M | -258 M | -225 M | - | - | - | - | - | - |
All numbers in USD currency
Quarterly Balance Sheet Adaptive Biotechnologies Corporation
2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Long Term Debt |
133 M | 132 M | 132 M | 131 M | 127 M | 94.2 M | 96.5 M | 125 M | 101 M | - | 105 M | 107 M | 108 M | 104 M | 95.3 M | 104 M | 104 M | 104 M | 104 M | 36.6 M | 36.6 M | 36.6 M | 36.6 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Liabilities |
335 M | 343 M | 346 M | 353 M | 356 M | 369 M | 368 M | 393 M | 396 M | - | 305 M | 319 M | 341 M | 340 M | 346 M | 373 M | 373 M | 373 M | 373 M | 341 M | 341 M | 341 M | 341 M | 29.9 M | 29.9 M | 29.9 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Deferred Revenue |
51.9 M | 52.2 M | 46.9 M | 48.6 M | 55.3 M | 57.9 M | 60.3 M | 64.1 M | 67.9 M | - | 83.5 M | 80.5 M | 80 M | 83.6 M | 78.3 M | 73.3 M | 73.3 M | 73.3 M | 73.3 M | 61 M | 61 M | 61 M | 61 M | 12.7 M | 12.7 M | 12.7 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Retained Earnings |
-1.27 B | -1.24 B | -1.19 B | -1.14 B | -1.07 B | -1.02 B | -977 M | -919 M | -879 M | - | -782 M | -719 M | -657 M | -602 M | -552 M | -512 M | -512 M | -512 M | -512 M | -365 M | -365 M | -365 M | -365 M | -296 M | -296 M | -296 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Assets |
559 M | 585 M | 620 M | 661 M | 718 M | 765 M | 791 M | 857 M | 884 M | - | 858 M | 923 M | 993 M | 1.03 B | 1.07 B | 1.12 B | 1.12 B | 1.12 B | 1.12 B | 912 M | 912 M | 912 M | 912 M | 333 M | 333 M | 333 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Cash and Cash Equivalents |
38.1 M | 59.8 M | 71.2 M | 65.1 M | 88.7 M | 109 M | 94.6 M | 90 M | 218 M | - | 115 M | 139 M | 122 M | 184 M | 174 M | 123 M | 123 M | 123 M | 123 M | 96.6 M | 96.6 M | 96.6 M | 96.6 M | 55 M | 55 M | 55 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Book Value |
224 M | 241 M | 275 M | 308 M | 362 M | 396 M | 424 M | 464 M | 488 M | - | 553 M | 604 M | 652 M | 693 M | 726 M | 743 M | 743 M | 743 M | 743 M | 571 M | 571 M | 571 M | 571 M | 303 M | 303 M | 303 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Shareholders Equity |
224 M | 242 M | 275 M | 308 M | 362 M | 396 M | 424 M | 464 M | 488 M | 518 M | 553 M | 604 M | 652 M | 693 M | 726 M | 743 M | 743 M | 743 M | 743 M | 571 M | 571 M | 571 M | 571 M | -258 M | -258 M | -258 M | -234 M | -225 M | - | - | - | -190 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency